Mereo BioPharma Group plc (FRA:MAH0)

Germany flag Germany · Delayed Price · Currency is EUR
1.595
+0.065 (4.25%)
Nov 25, 2025, 4:00 PM EST
-50.00%
Market Cap251.87M
Revenue (ttm)426.15K
Net Income (ttm)-35.43M
Shares Outn/a
EPS (ttm)-0.22
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,453
Average Volume103
Open1.515
Previous Close1.530
Day's Range1.515 - 1.595
52-Week Range1.300 - 3.800
Betan/a
RSI49.29
Earnings DateMar 26, 2026

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 36
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol MAH0
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.